Syros Pharmaceuticals Inc (NASDAQ:SYRS)‘s stock had its “outperform” rating reissued by equities research analysts at Wedbush in a report released on Monday. They presently have a $18.00 target price on the stock, down from their prior target price of $22.00. Wedbush’s target price would indicate a potential upside of 12.92% from the company’s previous close.
A number of other equities research analysts have also recently issued reports on SYRS. Zacks Investment Research upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 23rd. Oppenheimer Holdings Inc. restated a “buy” rating and issued a $28.00 price objective on shares of Syros Pharmaceuticals in a research note on Thursday, December 15th. Finally, Cann restated a “buy” rating and issued a $28.00 price objective on shares of Syros Pharmaceuticals in a research note on Monday, December 12th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Syros Pharmaceuticals has an average rating of “Buy” and a consensus price target of $21.00.
Syros Pharmaceuticals (NASDAQ:SYRS) traded up 0.56% during trading on Monday, reaching $16.03. The company had a trading volume of 39,960 shares. Syros Pharmaceuticals has a 52 week low of $8.16 and a 52 week high of $21.50. The firm’s market capitalization is $374.78 million. The company’s 50-day moving average is $11.54 and its 200 day moving average is $12.97.
Your IP Address:
Several large investors have recently made changes to their positions in SYRS. Spark Investment Management LLC bought a new stake in shares of Syros Pharmaceuticals during the third quarter valued at $160,000. Hamilton Lane Advisors LLC bought a new stake in shares of Syros Pharmaceuticals during the third quarter valued at $193,000. State Street Corp boosted its stake in shares of Syros Pharmaceuticals by 81.9% in the fourth quarter. State Street Corp now owns 45,447 shares of the company’s stock valued at $554,000 after buying an additional 20,468 shares in the last quarter. AWM Investment Company Inc. bought a new stake in shares of Syros Pharmaceuticals during the third quarter valued at $660,000. Finally, Alyeska Investment Group L.P. boosted its stake in shares of Syros Pharmaceuticals by 0.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 113,543 shares of the company’s stock valued at $1,381,000 after buying an additional 906 shares in the last quarter. Hedge funds and other institutional investors own 54.47% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.